Allergan’s new VEGF inhibitor may reduce injection burden for wet AMD
- Posted on: Jul 23 2018
- Leave a response
Findings from 2 late-stage trials hint that abicipar pegol performs on par with ranibizumab for neovascular AMD, but requires half the injections.
Source: AAO
Posted in: Uncategorized
